5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia

OBJECTIVE: To compare the risk of prostate cancer mortality among men treated with 5- alpha reductase inhibitors (5-ARIs) with those treated with alpha-adrenergic blockers (ABs) in community practice settings. PATIENTS AND METHODS: A retrospective matched cohort (N=174,895) and nested case-control s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mayo Clin Proc
Autors principals: Wallner, Lauren P., DiBello, Julia R., Li, Bonnie H., Van Den Eeden, Stephen K., Weinmann, Sheila, Ritzwoller, Debra P., Abell, Jill E., D’Agostino, Ralph, Loo, Ronald K., Aaronson, David S., Richert-Boe, Kathryn, Horwitz, Ralph I., Jacobsen, Steven J.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8080281/
https://ncbi.nlm.nih.gov/pubmed/28126151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.mayocp.2016.07.023
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars